FLT3 and acute myeloid leukemia: In this experiment, KG-1a and EoL-1 cells (FLT3-positive AML cells) were treated with Dox-HCl and several formulations of DMs at equivalent Dox doses of 0–2 μg/mL and their empty micelles at concentrations of 0–1 mg/mL for 48 h.